# Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

> **NCT01611675** · PHASE1 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Leflunomide

## Key facts

- **NCT ID:** NCT01611675
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Adverse Events
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611675, "Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01611675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*